JP2012529280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529280A5 JP2012529280A5 JP2012514528A JP2012514528A JP2012529280A5 JP 2012529280 A5 JP2012529280 A5 JP 2012529280A5 JP 2012514528 A JP2012514528 A JP 2012514528A JP 2012514528 A JP2012514528 A JP 2012514528A JP 2012529280 A5 JP2012529280 A5 JP 2012529280A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- ccr4
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 229940127121 immunoconjugate Drugs 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000003826 Chemokine CCL17 Human genes 0.000 claims 3
- 108010082169 Chemokine CCL17 Proteins 0.000 claims 3
- 102000006433 Chemokine CCL22 Human genes 0.000 claims 3
- 108010083701 Chemokine CCL22 Proteins 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010058285 Allergy to arthropod bite Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- 102000004498 CCR4 Receptors Human genes 0.000 claims 1
- 108010017317 CCR4 Receptors Proteins 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000738584 Homo sapiens C-C chemokine receptor type 4 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 108700021638 Neuro-Oncological Ventral Antigen Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- -1 coagulation Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 201000005311 drug allergy Diseases 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 238000004043 dyeing Methods 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 102000043444 human CCR4 Human genes 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 229960002340 pentostatin Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 229940068117 sprycel Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- 229960002110 vincristine sulfate Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18544809P | 2009-06-09 | 2009-06-09 | |
| GBGB0909906.0A GB0909906D0 (en) | 2009-06-09 | 2009-06-09 | Antibodies |
| GB0909906.0 | 2009-06-09 | ||
| US61/185,448 | 2009-06-09 | ||
| US30276810P | 2010-02-09 | 2010-02-09 | |
| US61/302,768 | 2010-02-09 | ||
| PCT/GB2010/001130 WO2010142952A2 (en) | 2009-06-09 | 2010-06-09 | Antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529280A JP2012529280A (ja) | 2012-11-22 |
| JP2012529280A5 true JP2012529280A5 (enExample) | 2013-07-25 |
| JP6141639B2 JP6141639B2 (ja) | 2017-06-07 |
Family
ID=40937121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514528A Expired - Fee Related JP6141639B2 (ja) | 2009-06-09 | 2010-06-09 | 抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8461304B2 (enExample) |
| EP (1) | EP2440579A2 (enExample) |
| JP (1) | JP6141639B2 (enExample) |
| CN (2) | CN104436191A (enExample) |
| EA (1) | EA201171464A1 (enExample) |
| GB (1) | GB0909906D0 (enExample) |
| WO (1) | WO2010142952A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CN103396486A (zh) | 2006-10-12 | 2013-11-20 | 中外制药株式会社 | 使用抗ereg抗体的癌症的诊断和治疗 |
| EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| GB201020738D0 (en) * | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| US10266599B2 (en) | 2010-12-07 | 2019-04-23 | Cancer Research Technology Limited | Antibodies which bind to the human CC chemokine receptor 4 and uses thereof |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| ES2800316T3 (es) * | 2011-06-13 | 2020-12-29 | Tla Targeted Immunotherapies Ab | Tratamiento del cáncer |
| US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| TWI593705B (zh) * | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| EP3511343A1 (en) * | 2012-05-04 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| JP6310845B2 (ja) | 2012-07-06 | 2018-04-11 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ−１関連脊髄症患者の治療方法および治療剤 |
| EP3473708B1 (en) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| WO2014035474A1 (en) * | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions and methods for treating cancer |
| GB2512857A (en) | 2013-04-09 | 2014-10-15 | Cancer Res Technology | Cancer biomarker |
| MX2015017852A (es) * | 2013-06-24 | 2016-08-11 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma. |
| JP6449272B2 (ja) * | 2013-07-08 | 2019-01-09 | ナンジン レジェンド バイオテック カンパニー，リミテッドＮａｎｊｉｎｇ Ｌｅｇｅｎｄ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | タンパク質の血清半減期を増加する組成物及び方法 |
| CN106413751A (zh) * | 2014-05-21 | 2017-02-15 | 辉瑞大药厂 | 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| EP3204418B1 (en) * | 2014-10-06 | 2020-03-25 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| GB201521447D0 (en) * | 2015-12-04 | 2016-01-20 | Ucb Biopharma Sprl | De novo antibody design |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| IL314733A (en) * | 2018-03-26 | 2024-10-01 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
| CN110759996B (zh) * | 2018-07-27 | 2022-09-06 | 深圳康体生命科技有限公司 | 一种gfp抗体 |
| CN111135310B (zh) * | 2019-12-24 | 2021-05-07 | 江苏省人民医院（南京医科大学第一附属医院） | 一种定制化t细胞表位疫苗的双靶向纳米药、其制备方法及应用 |
| CN114891117B (zh) * | 2022-04-26 | 2023-09-05 | 深圳市体内生物医药科技有限公司 | 一种靶向ccr8的嵌合抗原受体t细胞及其制备方法和应用 |
| KR20250122541A (ko) | 2022-10-25 | 2025-08-13 | 사이즈믹 테라퓨틱, 인코포레이티드. | 변이체 IgG FC 폴리펩티드 및 그 용도 |
| CN116693679B (zh) * | 2023-01-18 | 2025-11-11 | 中国人民解放军陆军军医大学 | 抗金黄色葡萄球菌α-溶血素的全人源单克隆抗体Hm0699及其应用 |
| CN117187180B (zh) * | 2023-11-03 | 2024-01-26 | 四川大学 | 一种Th17细胞及其培养方法和应用及其诱导液 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| AU2004201168A1 (en) | 1999-01-15 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US6342219B1 (en) | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| EP1050307A1 (en) | 1999-05-06 | 2000-11-08 | Applied Research Systems ARS Holding N.V. | CCR4 antagonists in sepsis |
| ATE402192T1 (de) * | 2000-03-03 | 2008-08-15 | Kyowa Hakko Kogyo Kk | Anti-ccr4 antikörper und fragmente davon |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2439279A1 (en) | 2001-02-28 | 2002-09-06 | Protein Design Labs, Inc. | Chemokine receptors and disease |
| CA2458627C (en) * | 2001-08-31 | 2013-09-10 | Kyowa Kirin Co., Ltd. | Human cdr-grafted antibody and antibody fragment thereof |
| EP1688436A4 (en) | 2003-10-08 | 2009-12-02 | Kyowa Hakko Kirin Co Ltd | ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY |
| JPWO2005053741A1 (ja) * | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬 |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| WO2009086514A1 (en) | 2007-12-28 | 2009-07-09 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| GB0909906D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| US8802442B2 (en) | 2011-11-30 | 2014-08-12 | Eric B. Wheeldon | Apparatus and method for the remote sensing of blood in human feces and urine |
-
2009
- 2009-06-09 GB GBGB0909906.0A patent/GB0909906D0/en not_active Ceased
-
2010
- 2010-06-09 CN CN201410645401.2A patent/CN104436191A/zh active Pending
- 2010-06-09 EP EP10723748A patent/EP2440579A2/en not_active Withdrawn
- 2010-06-09 CN CN201080035456.1A patent/CN102482355B/zh not_active Expired - Fee Related
- 2010-06-09 EA EA201171464A patent/EA201171464A1/ru unknown
- 2010-06-09 US US12/797,184 patent/US8461304B2/en not_active Expired - Fee Related
- 2010-06-09 JP JP2012514528A patent/JP6141639B2/ja not_active Expired - Fee Related
- 2010-06-09 WO PCT/GB2010/001130 patent/WO2010142952A2/en not_active Ceased
-
2013
- 2013-03-27 US US13/851,625 patent/US8822664B2/en not_active Expired - Fee Related
- 2013-04-25 US US13/870,058 patent/US9145461B2/en not_active Expired - Fee Related
-
2015
- 2015-08-25 US US14/834,934 patent/US20160208003A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529280A5 (enExample) | ||
| JP2014513519A5 (enExample) | ||
| CN102482355B (zh) | 抗体 | |
| WO2017118321A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| TW202144417A (zh) | Ｐｖｒｉｇ結合蛋白及其醫藥用途 | |
| JP2013519367A5 (enExample) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| CA3269788A1 (en) | Anti-lilrb1 antibody and uses thereof | |
| CA2850549A1 (en) | Antibodies against tl1a and uses thereof | |
| US12071479B2 (en) | Antibodies against ILT2 and use thereof | |
| CN109069606B (zh) | 干扰素β抗体及其用途 | |
| JP2025500971A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| JP2017517507A (ja) | 急性骨髄性白血病を特徴付け、治療する方法 | |
| EP4281474A2 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| AU2017219837A1 (en) | Antibodies for IL-17C | |
| JP2023541656A (ja) | 癌を治療するための抗ｉｌｔ４抗体またはそれと抗ｐｄ－１抗体との組合せの投与レジメン | |
| JP2023117408A (ja) | 慢性リンパ球性白血病のｂ細胞受容体を標的とする抗体およびその使用 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| JP2022513405A5 (enExample) | ||
| JP2025531168A (ja) | Ｐｄ－１アゴニスト抗体 | |
| KR20240137027A (ko) | 항인간 cxcl1 항체 | |
| WO2025153079A1 (en) | Method of treatment | |
| KR20260035361A (ko) | 폴리오바이러스 수용체에 대한 항체 및 이의 용도 | |
| WO2024243049A2 (en) | Antibodies and uses thereof |